References
- Akin MA, Gunes T, Coban D, et al. Pentraxin 3 concentrations of the mothers with preterm premature rupture of membranes and their neonates, and early neonatal outcome. J Matern Fetal Neonatal Med 2014. doi: 10.3109/14767058.2014.947574
- Yaman H, Cakir E, Akgul EO, et al. Pentraxin 3 as a potential biomarker of acetaminophen-induced liver injury. Exp Toxicol Pathol 2013;65:147–51
- Bonacina F, Baragetti A, Catapano AL, Norata GD. Long pentraxin 3: experimental and clinical relevance in cardiovascular diseases. Mediators Inflamm 2013;2013: Article ID 725102
- Iwata A, Miura S, Tanaka T, et al. Plasma pentraxin-3 levels are associated with coronary plaque vulnerability and are decreased by statin. Coron Artery Dis 2012;23:315–21
- Rosjo E, Myhr KM, Loken-Amsrud KI, et al. Increasing serum levels of vitamin A, D and E are associated with alterations of different inflammation markers in patients with multiple sclerosis. J Neuroimmunol 2014;271:60–5
- Bailey RL, Gahche JJ, Lentino CV, et al. Dietary supplement use in the United States, 2003–2006. J Nutr 2011;141:261–6